Withania somnifera Root Extract Using GC-MS and Nuclear Magnetic Resonance Spectroscopy
What is it about?
The objective of the study was to characterize and evaluate the impact of The Trivedi Effect® - Energy of Consciousness Healing Treatment (Biofield Energy Healing) on phytoconstituents present in the ashwagandha root extract using GC-MS and NMR.
Why is it important?
This study evaluated the impact of The Trivedi Effect® – Energy of Consciousness Healing Treatment (Biofield Energy Treatment) on metabolites of W. somnifera root extract and helped in a qualitative comparison between the treated and untreated ashwagandha sample using GC-MS and NMR. The GC-MS data indicated that the peak height and peak area of the treated sample was found to be altered compared with the control sample. The peak height of the phytoconstituents present in the treated sample was altered significantly in the range of -8.32% to 89.25% compared with the control sample. Similarly, the peak area of the treated sample was altered significantly in the range of – 4.28% to 216.30% compared with the control sample. Overall, the change in the peak area% of the treated sample was significantly altered in the range of -18.29% to 170.18% compared with the control sample. The GC-MS and NMR analysis results identified the presence of withanolides such as glyco-withanolides, alkaloids, and sugars in the root extract. Specifically, the peak area of 2,3,4,5- tetrahydropyridazine (1), methyl ethyl sulfoxide (2), 5,6- dihydro-2-methyl-4(H)pyran-3,4-dione (4), diethoxy-2- methyl-propane (5), 2,3,4,5-tetrahydroxy-tetrahydro-pyran (6), and 3,4-dimethyl-2(3H)-furanone (7) were significantly increased by 170.18%, 58.21%, 7.74%, 139.50%, 23.16%, and 45.63%, respectively in the treated sample compared with the control sample. On the contrary, the peak area% of 2-hydroxy-g-butyrolactone (3) was decreased by -14.96% in the treated ashwagandha compared with the control sample. From the results, it can be hypothesized that The Trivedi Effect® – Energy of Consciousness Healing Treatment might have the impact on the intrinsic physicochemical properties of the phytoconstituents present in the ashwagandha root extract. This could be the probable cause of alteration in the relative peak height and peak area of the treated sample. As a result, the concentrations of the phytoconstituents is assumed to be increased in the treated sample compared with the control sample. This treated ashwagandha root extract would be helpful for designing better pharmaceutical/nutraceutical formulations which might be providing a better therapeutic response against various diseases such as diabetes mellitus, allergies and septic shock; stress-related disorders like sleep disorder, insomnia, anxiety, depression, Attention Deficit Disorder (ADD), Attention Deficit Hyperactive Disorder (ADHD), mental restlessness (mind chattering), brain frog, low libido, impotency, lack of motivation, mood swings, fear of the future, confusion, migraines, headaches, forgetfulness, overwhelm, loneliness, worthlessness, indecisiveness, frustration, irritability, chronic fatigue, obsessive/compulsive behavior and panic attacks; inflammatory diseases and immunological disorders like Lupus, Systemic Lupus Erythematosus, Hashimoto Thyroiditis, Type 1 Diabetes, Asthma, Chronic peptic ulcers, Tuberculosis, Hepatitis, Chronic active hepatitis, Celiac Disease (gluten-sensitive enteropathy), Addison Disease, Crohn’s disease, Graves’ Disease, Pernicious and Aplastic Anemia, Sjogren Syndrome, Irritable Bowel Syndrome (IBS), Multiple Sclerosis, Rheumatoid arthritis, Chronic periodontitis, Ulcerative colitis, Chronic sinusitis, Myasthenia Gravis, Atherosclerosis, Vasculitis, Dermatitis, Diverticulitis, Rheumatoid Arthritis, Reactive Arthritis, Alopecia Areata Psoriasis, Scleroderma, Fibromyalgia, Chronic Fatigue Syndrome and Vitiligo; aging-related diseases like cardiovascular disease, arthritis, cancer, Alzheimer’s disease, dementia, cataracts, osteoporosis, diabetes, hypertension, glaucoma, hearing loss, Parkinson’s Disease, Huntington’s Disease, Prion Disease, Motor Neurone Disease, Spinocerebellar Ataxia, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Friedreich’s Ataxia and Lewy Body Disease, chronic infections and much more.
The following have contributed to this page: Mr Mahendra Kumar Trivedi, Gopal Nayak, Alice Branton, Cathryn Nykvist, Dianne Heather Vincent, Douglas Jay Konersman, Elizabeth Ann Feeney, Jay Prague, Joanne Lydia Starodub, Karan Rasdan, Karen Mie Strassman, Maire Anne Mayne, Mary Keesee, Pamela Clarkson Ansley, Ronald David Schmitz, Sharyn Marie Sodomora, and Dahryn Trivedi